博雅生物(300294.SZ)发布半年报 净利润升11.63%至2.13亿元
格隆汇8月28日丨博雅生物(300294.SZ)发布2019年半年度报告,实现营业收入约13.76亿元,同比增长25.95%;归属于上市公司股东的净利润约2.13亿元,同比增长11.63%;归属于上市公司股东的扣除非经常性损益后的净利润约2.00亿元,同比增长11.67%;基本每股收益0.50元。
报告期内,各业务板块经营概述如下:
1、血液制品业务方面
公司秉承“世界级血液制品企业、中国制药企业标杆”的战略目标,血液制品业务是公司的核心和支柱产业。公司在保障原料血浆稳定供应的同时,不断提升质量管理水平,改善生产效率,确保产品的收得率。报告期内,公司血液制品业务(不含复大医药的经销业务)实现营业总收入约4.72亿元,同比增长20.72%,占公司合并报表营业总收入的34.33%;净利润1.50亿元,同比增长12.76%,占归属于上市公司股东的净利润的70.15%。
2、非血液制品业务方面
报告期内,公司非血液制品业务主要为天安药业的糖尿病用药业务、新百药业生化类用药业务及复大医药药品经销业务等。报告期内,公司顺应市场,积极应对,努力提升产品市占率,同时加强成本管控,各板块经营效益均有提升,情况如下:
(1)天安药业糖尿病用药业务
报告期内,天安药业(根据公允价值调整后)营业收入1.70亿元,同比增长22.82%;净利润3346.52万元,同比增长34.64%。
(2)新百药业生化类用药业务
报告期内,新百药业(根据公允价值调整后)营业收入4.30亿元,同比增长46.65%;净利润4745.22万元,同比增长85.46%。
(3)复大医药药品经销业务
报告期内,复大医药实现收入3.34亿元,同比增长19.91%;净利润1751.81万元,同比增长12.21%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.